Tanzania and Mozambique have witnessed significant advancements in tuberculosis (TB) diagnosis through the implementation of decentralized testing platforms. The introduction of Molbio Truenat MTB assays has the potential to revolutionize TB detection by offering accurate point-of-care testing, thus enhancing accessibility and reducing out-of-pocket expenses for patients.
Enhancing Diagnostic Accessibility
Traditional hub-and-spoke models for TB testing often result in delayed diagnoses, contributing to higher morbidity and mortality rates. The TB-CAPT Core trial, a multicenter randomized controlled study, compared the effectiveness of decentralized Molbio Truenat platform against the conventional Xpert MTB/RIF Ultra testing in Tanzania and Mozambique. The findings indicate a substantial reduction in diagnostic costs per participant when utilizing decentralized testing methods.
Cost-Effectiveness Analysis
Economic evaluations revealed that, in Mozambique, the facility-based diagnostic cost per participant initiating treatment within seven days decreased from $853 with hub-and-spoke testing to $690 with decentralized testing. Similarly, in Tanzania, costs were marginally lower with decentralized approaches. Over a sixty-day period, Mozambique saw costs per treatment initiation drop to $581 from $678, while Tanzania experienced a significant decrease from $591 to $391.
- Decentralized testing significantly reduces immediate treatment initiation costs in Mozambique.
- Tanzania benefits from decreased long-term diagnostic expenses with decentralized methods.
- Testing volume and equipment utilization are critical factors influencing cost-effectiveness.
The study underscores the importance of equipment utilization in determining the economic viability of decentralized TB testing. High testing volumes can leverage the lower per-test costs associated with decentralized platforms, making them a financially sustainable option for low-and middle-income countries.
Adopting decentralized TB testing strategies not only improves the speed and accuracy of diagnoses but also presents a cost-effective solution that can be scaled across similar healthcare settings. Governments and health organizations should consider integrating such platforms to enhance TB control efforts, ultimately reducing the disease’s burden on affected populations.
Increased adoption of decentralized testing can lead to earlier treatment initiation, curbing TB transmission rates and improving patient outcomes. Moreover, the economic benefits realized through reduced diagnostic costs highlight the potential for significant healthcare savings. Stakeholders must prioritize the expansion of decentralized testing infrastructure to achieve sustained improvements in TB management.
This article has been prepared with the assistance of AI and reviewed by an editor. For more details, please refer to our Terms and Conditions. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author.
